Post-transplant Lymphoproliferative Disorders: A Rare Case of Primary Pericardial Involvement Epstein-Barr Virus-Correlated in Heart Transplantation

被引:0
作者
Toscano, G. [1 ]
Fabozzo, A. [1 ]
Fedrigo, M. [2 ]
Gambino, A. [1 ]
Angelini, A. [2 ]
Gerosa, G. [1 ]
机构
[1] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Heart Transplant Unit, I-35128 Padua, Italy
[2] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Pathol Anat, I-35128 Padua, Italy
关键词
SOLID-ORGAN TRANSPLANTATION; THERAPY;
D O I
10.1016/j.transproceed.2015.04.085
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Post-transplant lymphoproliferative disorders (PTLDs) are considered a fatal consequence of immunosuppression. We report a case of a 52-year-old patient, who underwent a cardiac transplantation and presented undefined recurrent episodes of pleuropericardial effusions without lymphoadenomegaly at chest radiographs and computed tomography. Histopathological analysis of the bioptic pericardium showed a specific chronic inflammation. Monitoring endomyocardial biopsies (EMBs) showed only 1 episodes of greater than grade 2R acute cellular rejection requiring immunosuppressive treatment, mild vasculitis in 2 subsequently EMBs while constantly negative for antibody-mediated rejection or infection. Only a post-mortem examination demonstrated the presence of an aggressive acute non-Epstein-Barr virus (EBV)-related proliferative disorder with unusual primitive localization into the pericardium and with coronary epicardial and intramyocardial necrotizing vasculitis and superimposed occlusive and subocclusive thrombosis. Recurrence of unexplained early pleuropericardial effusion and mild intramyocardial vasculitis should raise the suspicion of PTLD requiring reduction of immunosuppression, even in the setting of negative intramyocardial cellular infiltrate and tissue EBV-negative molecular assessment.
引用
收藏
页码:2287 / 2290
页数:4
相关论文
共 49 条
[31]   Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disorder: Potential Treatments and Implications for Nursing Practice [J].
Jimenez, Sarah .
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2015, 19 (01) :94-98
[32]   Post-transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: Presentation and response to treatment [J].
Aversa, S. M. L. ;
Stragliotto, S. ;
Marino, D. ;
Calabrese, F. ;
Rigotti, P. ;
Marchini, F. ;
Gambino, A. ;
Feltrin, G. ;
Boso, C. ;
Canova, F. ;
Solda, C. ;
Mazzarotto, R. ;
Burra, P. .
ACTA HAEMATOLOGICA, 2008, 120 (01) :36-46
[33]   Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities [J].
Al Hamed, Rama ;
Bazarbachi, Abdul Hamid ;
Mohty, Mohamad .
BONE MARROW TRANSPLANTATION, 2020, 55 (01) :25-39
[34]   A Scheduled Program of Molecular Screening for Epstein-Barr Virus Decreases the Incidence of Post-transplantation Lymphoproliferative Disease in Pediatric Liver Transplantation [J].
Soriano-Lopez, D. P. ;
Alcantar-Fierros, J. M. ;
Hernandez-Plata, J. A. ;
Gonzalez-Jorge, A. L. ;
Velazquez-Ramos, S. ;
Flores-Hernandez, M. A. ;
Fuentes, V. ;
Castaneda, P. ;
Nieto, J. ;
Sanchez, J. L. ;
Lopez, B. ;
Valencia-Mayoral, P. ;
Varela-Fascinetto, G. .
TRANSPLANTATION PROCEEDINGS, 2016, 48 (02) :654-657
[35]   Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature [J].
Anderson-Smits, Colin ;
Baker, Erin R. ;
Hirji, Ishan .
TRANSPLANT INFECTIOUS DISEASE, 2020, 22 (06)
[36]   Non-uniform in vivo Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease [J].
Burns, David M. ;
Ryan, Gordon B. ;
Harvey, Caroline M. ;
Nagy, Eszter ;
Hughes, Simon ;
Murray, Paul G. ;
Russell, Nigel H. ;
Fox, Christopher P. ;
Long, Heather M. .
FRONTIERS IN IMMUNOLOGY, 2019, 10
[37]   Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation [J].
Lieberman, Frank ;
Yazbeck, Victor ;
Raptis, Anastasios ;
Felgar, Raymond ;
Boyiadzis, Michael .
JOURNAL OF NEURO-ONCOLOGY, 2012, 107 (02) :225-232
[38]   Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases [J].
Kim, Nayoun ;
Sohn, Hyun-Jung ;
Oh, Joo Hyun ;
Jeon, Young-Woo ;
Lee, Hyun-Joo ;
Cho, Hyun-Il ;
Chung, Byung Ha ;
Yang, Chul-Woo ;
Kim, Tai-Gyu ;
Cho, Seok-Goo .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (05) :596-603
[39]   In vitro and in vivo evidence that the switch from c for updates calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder [J].
Thieme, Constantin J. ;
Schulz, Malissa ;
Wehler, Patrizia ;
Anft, Moritz ;
Amini, Leila ;
Blazquez-Navarro, Arturo ;
Stervbo, Ulrik ;
Hecht, Jochen ;
Nienen, Mikalai ;
Stittrich, Anna -Barbara ;
Choi, Mira ;
Zgoura, Panagiota ;
Viebahn, Richard ;
Schmueck-Henneresse, Michael ;
Reinke, Petra ;
Westhoff, Timm H. ;
Roch, Toralf ;
Babel, Nina .
KIDNEY INTERNATIONAL, 2022, 102 (06) :1392-1408
[40]   Hepatitis C Virus Infection Can Affect Lymphoproliferative Disorders Only as a Cofactor for Epstein-Barr Virus in Liver Transplant Recipients: PTLD.Int Survey [J].
Khedmat, Hossein ;
Taheri, Saeed .
EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2012, 10 (02) :141-147